Carlsmed, Inc. (CARL)
| Market Cap | 247.00M |
| Revenue (ttm) | 50.51M |
| Net Income (ttm) | -30.22M |
| Shares Out | 27.23M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,697 |
| Open | 9.79 |
| Previous Close | 9.86 |
| Day's Range | 9.02 - 10.04 |
| 52-Week Range | 8.50 - 17.19 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 19.25 (+112.24%) |
| Earnings Date | May 5, 2026 |
About CARL
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California. [Read more]
Financial Performance
In 2025, Carlsmed's revenue was $50.51 million, an increase of 85.94% compared to the previous year's $27.17 million. Losses were -$30.22 million, 21.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CARL stock is "Strong Buy." The 12-month stock price target is $19.25, which is an increase of 112.24% from the latest price.
News
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will parti...
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will rep...
Carlsmed Transcript: 25th Annual Needham Virtual Healthcare Conference
Aprevo's digital, AI-driven spine surgery platform has demonstrated strong clinical outcomes, including a 74% reduction in reoperations, and is expanding rapidly in both lumbar and cervical markets. Elevated reimbursement, robust surgeon adoption, and new product launches support a 44% growth outlook for 2024.
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th...
Carlsmed Transcript: 2026 CG Musculoskeletal Conference
Rapid revenue growth and strong clinical validation drive adoption of a personalized spine surgery platform, now expanded to both lumbar and cervical procedures. New reimbursement wins and technological innovations support continued U.S. market expansion.
Carlsmed Earnings Call Transcript: Q4 2025
Achieved 86% revenue growth in 2025, driven by strong lumbar platform performance and new cervical product launches. Gross margins expanded to 75.3%, and 2026 revenue is guided to grow 44% at the midpoint. Cash position remains strong after a successful IPO.
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsme...
Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 ...
Carlsmed Announces first corra™ personalized Cervical Plating Procedure
The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfoli...
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will repo...
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery u...
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Jou...
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting a...
Carlsmed Transcript: Piper Sandler 37th Annual Healthcare Conference
A next-generation med tech platform for spine surgery has demonstrated a 74% reduction in reoperation rates and is expanding from lumbar to cervical procedures, targeting a combined 800,000 annual U.S. cases. Enhanced reimbursement, rapid production, and a capital-light model drive strong growth and adoption.
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop First 50+ cervical cases completed; observations o...
Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference
CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting ...
Carlsmed Earnings Call Transcript: Q3 2025
Q3 2025 saw 98% revenue growth, 76% gross margins, and a 70% increase in surgeon users, with strong clinical data supporting reduced revision rates. Full-year revenue guidance was raised to $49–$50 million, and the company is well-positioned for the upcoming cervical fusion launch.
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, ...
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will repo...
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results
Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Compa...
Carlsmed Earnings Call Transcript: Q2 2025
Q2 2025 revenue nearly doubled year-over-year to $12.1 million, driven by strong surgeon adoption and procedure growth. Full-year revenue is guided to $45.5–$47.5 million, with continued expansion in both lumbar and upcoming cervical fusion markets.
Carlsmed® Reports Second Quarter 2025 Financial Results
Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Compa...